
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
The positive outlook for IQVIA Holdings is supported by robust growth in its Flexible Solutions Provider (FSP), Real World Evidence (RWE), and Clinical Trial Management System (CSMS) segments, which exhibited year-over-year increases in Q3. The company has demonstrated resilience in its commercial operations, bolstered by improved client decision timelines and a strong pipeline related to recent drug launches, contributing to a low-teens year-over-year increase in Request for Proposals (RFP) flow. Additionally, IQVIA's pricing environment has improved, allowing the company to turn down less favorable deals, while R&D Services (R&DS) is projected to achieve a growth rate exceeding 4% on a constant currency basis, excluding COVID-19 impacts.
Bears say
The financial analysis reveals several fundamental issues contributing to a negative outlook for IQVIA Holdings's stock. Year-over-year constant currency growth has declined to 3.8%, down from 6.8% in the previous quarter, indicating a weakening growth trajectory that may not meet management's expectations for 2026, which they deemed disappointing if growth falls below 5%. Additionally, challenges such as difficult year-over-year comparisons, concerns over potential revenue growth slowdowns in real-world evidence (RWE), and margin pressure from passthroughs further exacerbate the company's financial vulnerabilities, compounded by the impact of rising interest rates on earnings.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares